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Because minimal information is available about surfactant
metabolism in bronchopulmonary dysplasia, we measured half-
lives and pool sizes of surfactant phosphatidylcholine in very
preterm baboons recovering from respiratory distress syndrome
and developing bronchopulmonary dysplasia, using stable iso-
topes, radioactive isotopes, and direct pool size measurements.
Eight ventilated premature baboons received 2H-DPPC (dipalmi-
toyl phosphatidylcholine) on d 5 of life, and radioactive 14C-
DPPC with a treatment dose of surfactant on d 8. After 14 d, lung
pool sizes of saturated phosphatidylcholine were measured. Half-
life of 2H-DPPC (d 5) in tracheal aspirates was 28  4 h (mean
 SEM). Half-life of radioactive DPPC (d 8) was 35  4 h.
Saturated phosphatidylcholine pool size measured with stable
isotopes on d 5 was 129  14 mol/kg, and 123  11 mol/kg
on d 14 at autopsy. Half-lives were comparable to those obtained
at d 0 and d 6 in our previous baboon studies. We conclude that
surfactant metabolism does not change during the early devel-
opment of bronchopulmonary dysplasia, more specifically, the
metabolism of exogenous surfactant on d 8 is similar to that on
the day of birth. Surfactant pool size is low at birth, increases
after surfactant therapy, and is kept constant during the first 2 wk
of life by endogenous surfactant synthesis. Measurements with
stable isotopes are comparable to measurements with radioactive
tracers and measurements at autopsy. (Pediatr Res 52: 724–729,
2002)
Abbreviations
RDS, respiratory distress syndrome
BPD, bronchopulmonary dysplasia
GA, gestational age
DPPC, dipalmitoyl phosphatidylcholine
Sat PC, saturated phosphatidylcholine
PG, phosphatidylglycerol
Sp, sphingomyelin
Since the introduction of surfactant therapy for the treatment
of neonatal RDS, mortality and morbidity due to RDS have
dramatically decreased (1). Most studies of surfactant metab-
olism have been performed in animals with radioactive tracers
used to measure surfactant synthesis, half-life of surfactant,
pool sizes, and influences of hormonal treatments (2, 3). Sur-
factant metabolism changes with lung injury and with devel-
opment. Newborn animals have less de novo synthesis and a
longer biologic half-life of phosphatidylcholine (PC) than adult
animals, but newborns also have higher rates of surfactant
recycling (3). In adult animals, acute lung injury or oxygen
exposure change surfactant composition and pool sizes (4).
Despite the progress in neonatal care, many very preterm
infants develop BPD characterized by lung injury, inflamma-
tion, and an arrest in alveolar development (5). It is presently
unclear whether the surfactant system is involved in the devel-
opment of BPD. Most studies of surfactant metabolism in
newborn animals and humans have been performed during the
first days of life, during the acute phase of RDS. Almost no
information is available about surfactant metabolism beyond
the first week during the development of BPD (6). Infants who
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develop BPD have an altered phospholipid composition of
surfactant (7, 8), and surfactant therapy in infants developing
BPD resulted in a transient improvement of oxygenation (9). In
ventilated preterm baboons developing BPD, the abnormal
alveolar development and injury is similar to that found in
humans (10). These very preterm baboons have a large in-
crease in intracellular surfactant pool size during the first few
days, but surfactant secretion to the alveolar space is very
limited (11). Surfactant lipid and protein composition and
surfactant function is abnormal in baboons developing BPD
(11, 12). However, there is no information about the metabo-
lism of the sat PC component of surfactant as the animals
develop BPD.
We recently used stable isotopes to study the surfactant
metabolism in premature human neonates (13, 14). However, a
validation of the method using stable isotopes has not been
performed because radioactive isotopes are medically and eth-
ically not accepted in human newborns, and lung pool size of
surfactant has only been measured in newborns who did not
survive (15).
In the present study, we evaluated surfactant metabolism in
very preterm ventilated baboons during the acute phase of RDS
(d 1–3), the phase of recovery from RDS, and the development
of BPD. We measured surfactant half-lives and pool sizes in
each individual baboon during the first 2 wk of life. We were
specifically interested in the changes of the surfactant metab-
olism in the second week of life during the development of
BPD. Furthermore, we compared the surfactant half-life and
surfactant pool size measured with stable isotopes to measure-
ments made with radioactive isotopes and direct measurements
of pool size at autopsy.
METHODS
Study protocol. The animal studies were performed at the
Southwest Foundation for Biomedical Research (San Antonio,
TX, U.S.A.), as described before and conformed to the Amer-
ican Association for Accreditation of Laboratory Animal Care
guidelines (11).
We studied surfactant metabolism in eight baboons (GA
124–127 d; full term at 185 d) using stable isotopes and
radioactive isotopes with surfactant treatment at different times
over a 14-d period of ventilation (Fig. 1). The baboons received
unlabeled surfactant at birth [100 mg/kg Survanta (beractant),
Abbott Laboratories, Abbott Park, IL, U.S.A.]. At 120 h (d 5),
they received a tracer dose of 5 mg/kg (6.8 mol/kg) deute-
rium (stable isotope) labeled DPPC (2H-DPPC, where three
deuterium labels are present in the palmitoyl-groups) (L-3-
phosphatidylcholine dipalmitoyl-D6, Doosan Serdary Re-
search Laboratories, NJ, U.S.A.) intratracheally. The 2H-DPPC
was used to measure the disappearance of labeled PC palmitate
from the tracheal aspirates and to calculate surfactant pool size.
Day 5 was chosen because a 3-d interval is needed to reliably
calculate surfactant half-life and pool size. At 192 h (d 8), these
eight baboons received a treatment dose of 100 mg/kg (68
mol sat PC/kg) Survanta labeled with radioactive [14C]cho-
line-labeled DPPC (5 Ci 14C-DPPC/kg birth weight). A 6-d
interval from d 8 to d 14 was chosen to compare the surfactant
half-life and pool size with our previous data (11). In that
study, we measured the surfactant metabolism in the first 6 d of
life. Over the interval from birth to d 6, most of the PC in the
surfactant treatment given at birth was degraded. Tracheal
aspirates were obtained every 12 h for 14 d as described before
(11). At 336 h (d 14), the animals were killed with pentobar-
bital. Alveolar wash and lung homogenates were retrieved as
described before (11).
Analytical procedures. The tracheal aspirates, alveolar
washes, and lung homogenates were processed as described
before (16). The PC fraction of the tracheal aspirates was
isolated by thin-layer chromatography and derivatives of PC
palmitate were formed during incubation with 0.015 mL N-
methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide (MTB-
STFA, Pierce, Onmilabo, Breda, The Netherlands) and 0.015
mL pyridine, to measure 2H-enrichment. Analysis of radioac-
tive isotopes in tracheal aspirates, alveolar washes, and lung
homogenates were performed as described before (11). Fatty
acid composition of surfactant PC in tracheal aspirates was
measured by gas chromatography (5890 series II, Hewlett-
Packard, Amstelveen, The Netherlands (17).
Determination of enrichment of stable isotope. The 2H
enrichment of surfactant PC-palmitate was measured with a
Carlo Erba GC8000 gas chromatograph coupled to a Fisons
MD-800 mass spectrometer (Interscience BV, Breda, The
Netherlands). One microliter of the derivative was injected on
a fused silica capillary column of 25 m  0.22 mm, coated
with 0.11 m HT-5 (SGE, Victoria, Australia). The enrichment
was expressed as mol percent excess (MPE), which represents
the molar percent of the labeled molecule (m3 palmitate),
Figure 1. Schematic representation of the study protocol. Eight baboons received unlabeled surfactant at birth, exogenous 2H-DPPC on d 5, and on d 8 they
received exogenous 14C-DPPC together with a treatment dose of Survanta. After 14 d of ventilation, direct surfactant sat PC pool size measurements were
performed at autopsy.
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corrected for baseline enrichment (before isotope infusion)
(18).
Calculations. Calculations were performed as described pre-
viously (13, 14). As palmitic acid is by far the most abundant
fatty acid in surfactant PC, calculations were performed for
palmitic acid only.
The half-life of 2H-DPPC and 14C-DPPC was calculated by
exponential curve fitting of the final monoexponential part (y
 a*e-kt) of the downslope of the curve of 2H-enrichment and
specific activity of 14C versus time, respectively [t1/2  ln
(2)/k].
The apparent lung surfactant pool size was calculated by
using the linear regression line representing the decay of the
log-transformed 2H-enrichment over time. Extrapolation back
to the time of administration (t  120 h) represents the
2H-enrichment at t 120, from which we calculate the dilution
of the tracer. The endogenous apparent pool size was calcu-
lated by multiplying the amount of exogenous DPPC with the
dilution factor. The endogenous apparent pool size was cor-
rected for the amount of exogenous 2H-DPPC administered,
and expressed as micromoles per kilogram sat PC by using the
fatty acid composition of PC obtained by GC.
Data analysis. Data are presented as mean  SEM. Differ-
ences between groups were analyzed by one-way ANOVA.
Significance was accepted at p  0.05.
RESULTS
We studied eight baboons with a mean birth weight of 386
 11 g (four females, four males).
On d 5, the baboons received a trace dose of 2H-labeled
DPPC (6.8 mol/kg). The values of the 2H-enrichment of PC
palmitate in sequential tracheal aspirates versus time were used
to calculate a half-life of 28  4 h (Fig. 2B, Table 1). The
half-life was calculated from the final monoexponential part of
the decrease in 2H-enrichment in each baboon.
On d 8, the baboons received a therapeutic dose of radioac-
tive surfactant (100 mg/kg Survanta, 68 mol sat PC/kg). The
half-life, calculated by exponential curve fitting of the final
monoexponential part of the downslope of the curve of the
specific activity of 14C-DPPC in airway samples versus time
curve, was 35  4 h (Fig. 2A, Table 1).
We compared the results of these eight baboons with our
previous data for surfactant metabolism in similar premature
baboons that were ventilated for 6 d (11, 16). The previous
studies in very premature baboons (GA 125  2 d) were
performed by the same investigators, using the same pre- and
postnatal care. The half-life of 14C-DPPC given on d 0 in the
previous study is shown in Table 1. The results show similar
half-lives on d 0, 5, and 8 after birth.
The apparent lung sat PC pool size on d 5 was 129  14
mol/kg (Table 1). The pool size was calculated from the
monoexponential decrease in 2H-enrichment, by using the
linear regression line representing the decay of the log-
transformed 2H-enrichment over time. On d 14, the pool size of
sat PC measured for the total lung was 123  11 mol/kg
(Table 1). Total lung pool size on d 0 and 6 from previous
experiments are shown for comparison (11). There was no
significant difference between pool sizes on d 5, 6, and 14
(one-way ANOVA, p  0.065).
DISCUSSION
BPD was initially described as severe injury of the preterm
lung resulting from mechanical ventilation and oxygen expo-
sure (19). With the introduction of surfactant therapy and
prenatal corticosteroids, BPD now primarily develops in very
preterm infants weighing 1 kg, without severe RDS. This
new BPD may be primarily caused by an arrest of lung
development (20). We report here surfactant metabolism dur-
ing the early phase of BPD in very premature baboons. Half-
life and apparent lung sat PC pool size were calculated after
endotracheal instillation of a tracer dose of deuterium-labeled
DPPC on d 5 after birth. On d 8 of life, half-life was measured
after endotracheal radiolabeled DPPC together with a treatment
dose of surfactant, and pool size measurements from whole
lung were made on d 14. We show that although the baboons
recover from RDS and develop the early phase of BPD,
surfactant sat PC half-life and surfactant sat PC pool size do
not change. It remains presently unclear whether the surfactant
metabolism plays a role in the pathogenesis of BPD.
Most studies of surfactant kinetics have been performed over
a short time course. In the present study, we were able to
Figure 2. Decay of the label in tracheal aspirates after endotracheal admin-
istration of labeled DPPC. (A) Specific activities of sat PC from tracheal
aspirates after treatment of baboons with 14C-DPPC labeled 100 mg/kg
Survanta on d 8. Specific activities as CPM/mol sat PC were normalized to
the specific activity of the surfactant used to treat the preterm baboons. (B)
Mean  SEM 2H-enrichment of surfactant PC-associated palmitate in sequen-
tial tracheal aspirates of eight baboons (125 GA) after 2H-DPPC (stable
isotope) administration at d 5 (t  120 h).
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evaluate surfactant metabolism during the first 2 wk of life in
the same animal. In our previous study, we measured surfactant
synthesis in the acute phase of RDS, and surfactant half-life
and pool size were studied after treatment with surfactant at
birth. By using a 14-d ventilated preterm baboon model, which
shows abnormal alveolar development and injury similar to
that found in humans (21), we were now able to measure
surfactant kinetics during the development of BPD, more
specifically on d 5, and after surfactant treatment on d 8. Our
measurements in the preterm baboon are summarized in Figure
3. We measured a low sat PC pool size at birth, which was
increased at d 6 after surfactant treatment. As 84% of the
14C-DPPC given at birth was degraded by d 6 (11), the increase
of the total sat PC pool size resulted from endogenous synthe-
sis of surfactant. In the second week of life, the pattern of
surfactant metabolism was similar: about 90% of the 14C-
DPPC administered at d 8 was degraded by d 14 (22), whereas
the total lung sat PC pool size did not change significantly.
Sat PC pool size on d 5, measured with stable isotopes, was
129 mol/kg and was comparable to the total lung pool size
measured at autopsy on d 14 (123 mol/kg) in the same
animal. The trend of a larger sat PC pool size at autopsy on d
6 in the previous study (166 mol/kg) (11) compared with the
pool size on d 5 in the current study, may be explained by
measurements in different animals. It is also unclear to what
extent an abnormal surfactant metabolism influences the mea-
surements. In the previous study, we found very high tissue
pools, but low alveolar pool sizes of surfactant, caused by a
low secretion of de novo synthesized sat PC into the alveolar
space. No other studies have investigated the evolution of
surfactant pool sizes in premature animals during a longer
period. A study in term rats found a progressive decrease in
total lung sat PC pool sizes corrected for weight during the first
100 d after birth (from ~125 mol/sat PC/kg to ~5 mol/sat
PC/kg) (23).
Jackson et al. (24) measured a total lung pool size of sat PC
of ~45 mol/kg in preterm monkeys with RDS at birth.
However, these monkeys were not as premature as the baboons
in the present study (83% versus 68% of the term gestational
age) and they did not receive exogenous surfactant. Preterm
lambs delivered at 132 d gestational age had total lung sat PC
pool sizes of ~60 mol/kg without surfactant treatment (25)
and ~80 mol/kg sat PC when treated with surfactant (26). In
preterm neonates, using stable isotopes, we previously mea-
sured an apparent sat PC pool size of ~8 mol/kg and ~22
mol/kg before and after surfactant therapy, respectively (14).
Hallman et al. (27) showed an apparent pool size of ~12
mol/kg in human preterm neonates with RDS. They used PG
Table 1. Surfactant half-lives and sat PC pool sizes
D0*
14C-DPPC/autopsy
D5
2H-DPPC
D6*
autopsy
D8
14C-DPPC
D14
autopsy
Half-life (h) 30 28  4 — 35  4 —
Pool size (mol/kg sat PC) 30 129  14 166 11 — 123  11
Half-life and sat PC pool size expressed as mean  SEM. On d 5, the baboons received 2H-DPPC (stable isotope) endotracheally, on d 8 they received
14C-DPPC (radioactive) with Survanta (100 mg/kg) endotracheally, and on d 14 the baboons were killed.
* The results are compared with results reported previously (11).
Figure 3. An overview of the surfactant metabolism during the first 2 wk of life in the very premature ventilated baboon. At birth the baboons received 68
mol/kg sat PC Survanta, from which 84% was degraded at d 6 [results reported previously (11)]. Pool size at d 6 was 166 mol/kg sat PC, which indicates
an increase of pool size by endogenous surfactant synthesis. In the second week of life during the early development of BPD, the endogenous surfactant pool
size remains fairly constant and catabolism is similar to that in the first week after a dose of 68 mol/kg sat PC Survanta.
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as label to measure surfactant pool size. With the same method,
Griese et al. (28) calculated an apparent pool size of ~13
mol/kg sat PC in preterm neonates with RDS. However, the
pool size measurements in humans were made with a tracer
together with one or more therapeutic doses of surfactant,
whereas in the present study only a trace dose of surfactant was
used on d 5. The pool sizes measured in the human studies
probably represent the alveolar pool sizes. Their apparent pool
size was comparable with the alveolar pool size found in other
studies (~20 mol/kg) (15). In the current study, the pool size
measured with stable isotopes likely represents the total lung
pool size as the small amount of tracer is quickly taken up by
the lung cells in contrast to the large treatment doses.
The half-life of DPPC over the interval from d 5 to d 8, using
stable isotopes, was 28 4 h, which was similar to the half-life
measured with radioactive DPPC from d 8 onward. Similar
results were found at d 0, using radioactive DPPC, in our
previous study (11). Thus, the half-life of surfactant did not
change during the first 2 wk of life in the very premature
baboon. The same half-life of 35 h was found in preterm lambs
using PG as tracer in alveolar washes (29). In one study in term
newborn lambs, endotracheally injected 3H-PC had a very long
half-life of 6 d (30). Possibly, variations of half-lives are due to
differences in maturity. In premature infants treated with am-
niotic fluid-derived surfactant containing PG, the half-life was
30 h (27). In another study in premature infants using PG and
Sp as markers, half-life of PG was 43 h and 105 h after
treatment with Alveofact and Survanta, respectively, and the
half-life of Sp was 97 h after treatment with Survanta (28). The
differences in half-lives could be explained by the different
composition of the two surfactants and the different doses
given. Comparable results were found in human premature
neonates using stable isotopes (14). Preterm infants received
two doses of surfactant labeled with 13C-atoms, 5 h and 32 h
after birth, respectively. The calculated half-life was 34 h and
17 h, respectively. All these studies in human neonates calcu-
lated half-life from the disappearance of the label (PG, Sp, and
13C) from tracheal aspirates, as in the current study. The
half-life of a trace amount of labeled DPPC (d 5) in the present
study was not influenced by the administration of treatment
doses of surfactant (100 mg/kg) (d 8), which is in agreement
with Hallman et al. (27), and with our previous results (31).
However, in mice the half-life for 3H-DPPC in total lung
increased ~2-fold after the instillation of 45 mol/kg sat PC
compared with a trace dose (32). Nevertheless, further increase
of the dose had no effect on the half-life.
As a secondary goal, we compared the method of DPPC
half-life and sat PC pool size measurements using stable
isotopes with that of radioactive isotopes and surfactant pool
size measurements at autopsy in very premature ventilated
baboons. The results obtained with the use of stable isotopes
were comparable to the results obtained with radioactive trac-
ers and tissue measurements of pool size. Estimation of sur-
factant half-life and pool size by the isotope dilution method is
based on several assumptions. The distribution of the exoge-
nous surfactant and the endogenous surfactant has to be simi-
lar, the phospholipid composition in the various surfactant
compartments has to be uniform, the surfactant system has to
be pulse labeled, there should be no endogenous synthesis of
the label, and the pool size after exogenous surfactant has to be
constant. It is reasonable to assume that most of the assump-
tions have been fulfilled as has been extensively discussed by
Hallman et al. (27)and by Torresin et al. (14).
In conclusion, The metabolism of surfactant PC did not
change during the recovery from RDS and the development of
BPD. Very preterm baboons have low sat PC pool size at birth.
Treatment with surfactant increased instantaneously the total
lung sat PC pool size, which was kept relatively constant by
endogenous surfactant synthesis. Half-lives of surfactant PC
did not change during the first 2 wk of life. We also showed
that stable isotopes are a valid tool for studying surfactant
metabolism in vivo. This method can be easily applied to
human neonates, which will enable us to better understand the
role of surfactant in different neonatal lung diseases.
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